Polypeptide CDMOs: shengnuo Biological

From the perspective of the income scale of polypeptide CDMO, shengnuo Biological is 80 million yuan.

In this case, from the perspective of the scale of polypeptide drug revenue in 2020, shengnuo Biological is 288 million yuan.

1. shengnuo Biological Income is mainly from the CDMO business of polypeptide preparations and polypeptide APIs. The revenue in 2020 will reach RMB 208,000,000 and RMB 80,000,000 respectively.

Among them, the revenue of polypeptide preparations is mainly composed of oxytocin and octreotide, which together account for 76.5% of the preparation business in 2020; the polypeptide bulk drugs are mainly composed of bivalirudin and somatostatin, which together account for 65% of the bulk drugs in 2020.

In the past three years, preparations and CDMOs have maintained rapid growth, with growth rates reaching 26.98% and 45.57% respectively, and APIs are relatively stable.